Second Pivotal Phase III Study Of Gilead’s Darusentan For Resistant Hypertension Misses Primary Endpoints

Gilead Sciences, Inc. (Nasdaq:GILD) announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo…

Go to Source

People who read this also read

• Gilead Terminates Phase II Clinical Trial Of GS 9450 In Patients With Chronic Hepatitis C
  Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number...
• Trophos Completes Patient Enrolment In Pivotal Phase 3 Efficacy Study Of Olesoxime In Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
  Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announced today the completion of patient enrolment with over 500 patients recruited into the pivotal phas...
• Zogenix Initiates Pivotal Phase 3 Clinical Trial For Novel Formulation Of Oral Controlled-Release Hydrocodone
  Zogenix, Inc. ("Zogenix"), a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain ...
• Antares Pharma Announces Completion Of Patient Enrollment In Phase 3 Pivotal Trial Of Anturol™ For The Treatment Of Overactive Bladder
  Antares Pharma, Inc. (NYSE Amex: AIS) announced that it has completed enrollment in the double-blind portion of the Company's Phase 3 clinical trial of Anturol™, its transdermal oxybutynin ATD™ gel for the treatment of overactive bladder (OAB). Top line data from this pivotal trial, which is being c...
• Novelos Therapeutics Pivotal Phase 3 Lung Cancer Trial Does Not Meet The Primary Survival Endpoint
  Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung c...